Présentation de l'entreprise
Anbio Biotechnology operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry, where it delivers in vitro diagnostics products across the European Union, Asia Pacific, North America, South America, Africa, and international markets. The company's product portfolio includes SARS-CoV-2 antigen rapid tests, SARS-CoV-2/influenza A/B antigen rapid tests, lateral flow immunoassays, and fluorescence immunoassays designed for diagnostic applications. As a publicly traded entity with the ticker NNNN, the company maintains a market capitalization of $1.13 billion and employs a workforce of 27 individuals to support its global distribution network. The valuation metrics reveal a significant disparity between the company's market capitalization of $1.13 billion and its annual revenue of $6.92 million, indicating that the market assigns a substantial premium to the firm's future growth potential and asset value rather than its current operational earnings power.
Santé financière
The company reported a trailing twelve-month revenue of $6.92 million and generated a net income of $2.57 million during the same period, while specific EBITDA figures are not disclosed in the available data. The substantial gap between the $6.92 million in revenue and the $2.57 million in net income highlights an exceptionally efficient cost structure, suggesting that operating expenses and cost of goods sold are tightly controlled to preserve profitability. Free cash flow data is not currently available for disclosure, which limits the immediate assessment of the company's cash generation capabilities from operations but does not preclude the existence of liquidity reserves. The balance sheet demonstrates a highly conservative posture with total cash holdings of $13.43 million against zero recorded debt, eliminating interest coverage risks and refinancing concerns. This liquidity position is further reinforced by a current ratio of 211.10, which indicates an overwhelming ability to meet short-term obligations with current assets. Return on Equity stands at 11.2%, demonstrating effective utilization of shareholder capital, while Return on Assets is recorded at 4.7%, reflecting the asset efficiency relative to the company's total asset base.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is reported at 430.83, whereas the forward P/E ratio is not available for comparison, implying that the market is currently pricing in earnings expectations that are not yet reflected in the historical multiples. The price-to-book ratio is exceptionally high at 41.16, signaling that the market values the company's equity at more than forty times its book value, which typically suggests a premium assigned to intangible assets, proprietary technology, or anticipated high-growth trajectories. Alternative valuation metrics such as the price-to-sales ratio of 163.95 and the EV/EBITDA ratio which is not available, further illustrate that investors are willing to pay a significant multiple relative to sales to secure a stake in the company. The stock has exhibited considerable price volatility over the past year, trading between a 52-week low of $5.89 and a 52-week high of $55.65, reflecting the speculative nature of the investment without a defined beta value to quantify market correlation. Without a specific beta value to cite, the price range movement alone underscores the asset's sensitivity to market sentiment and sector-specific developments within the medical diagnostics space.
Growth & Income
Revenue growth over the last year recorded a decline of -21.6%, contrasting sharply with earnings growth which increased by 2.8%, indicating that the company managed to improve its profitability despite a contraction in sales volume. This divergence suggests that the company may be benefiting from margin expansion or one-time gains that offset the drop in top-line revenue, a dynamic often seen in early-stage biotechnology firms optimizing their cost structures. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all generated earnings are retained within the business to fund research, development, or operational expansion rather than being distributed to shareholders. Consequently, the overall growth and income profile is characterized by reinvestment of capital and a reliance on capital appreciation driven by future product approvals and market penetration in global diagnostic markets.